Volume : 12, Issue : 11, November – 2025
Title:
A REVIEW ON PSORIASIS AND ITS MANAGEMENT
Authors :
Sakshi Suryakant Tipale , Vaishnavi Devidas Jaybhaye, Shubham Santosh Shinde, Mr.Swapnil P. Kulthe
Abstract :
In this literature review article, several relevant scientific studies and publications will be analyzed to provide an overview of psoriasis treatment. Aspects such as epidemiology, the significance of the disease, the theoretical framework that includes definition, diagnosis, treatment and complications will be addressed, and conclusions based on the available evidence will be presented.
Psoriasis is fundamentally an inflammatory skin condition with reactive abnormal epidermal differentiation and hyperproliferation affecting 2-3 % of world‟s population. Pathophysiology of the disease includes mainly the activation and migration of T cells to the dermis triggering the release of cytokines (tumor necrosis factor-alpha TNF-alpha, in particular) which lead to the inflammation and the rapid production of skin cells .
Psoriasis is a chronic skin disease that affects millions of people worldwide. Its etiology is not yet fully understood, but it is thought to be related to a combination of genetic, immunological and environmental factors. In this literature review article, several relevant scientific studies and publications will be analyzed to provide an overview of psoriasis treatment. Aspects such as epidemiology, the significance of the disease, the theoretical framework that includes definition, diagnosis, treatment and complications will be addressed, and conclusions based on the available evidence will be presented.
Key-Words: Psoriasis, Plaque psoriasis, Psoriatic arthritis, Phototherapy, Topical steroid, Inflammatory cells, manifestations, patches, psoriasis
Cite This Article:
Please cite this article in press Sakshi Suryakant Tipale et al., A Review On Psoriasis And Its Management, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1] Samuel M.L., Donald P.M., Hurley J.H. (1986). In Jr. Dermatology, Vol-I. W. B. Philadelphia Saunders Company, p. 204.
2] World Health, O. Global Report on Psoriasis; World Health Organization: Geneva, Switzerland, 2016.
3] Griffiths, C.E.M.; Armstrong, A.W.; Gudjonsson, J.E.; Barker, J. Psoriasis. Lancet 2021, 397, 1301–1315. [CrossRef]
4]Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019; 80(1):27-40.
5] Kimball AB, Wu EQ, Guérin A, Andrew PY, Tsaneva M, Gupta SR, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651 7.
6]Au S‑C, Yaniv S, Gottlieb AB. Psoriatic eye manifestations. Psoriasis Forum 2011;17;3:169‑79.
7]Gyldenløve, M.; Alinaghi, F.; Zachariae, C.; Skov, L.; Egeberg, A. Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review. Am. J. Clin. Dermatol. 2022, 23, 605–613. [CrossRef]
8]Hsieh, T.S.; Tsai, T.F. Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review. Dermatol. Ther. 2023, 13, 891–909. [CrossRef]
9]Pourani, M.R.; Abdollahimajd, F.; Zargari, O.; Shahidi Dadras, M. Soluble biomarkers for diagnosis, monitoring, and therapeutic response assessment in psoriasis. J. Dermatol. Treat. 2022, 33, 1967–1974. [CrossRef]
10]Lwin, S.M.; Snowden, J.A.; Griffiths, C.E.M. The promise and challenges of cell therapy for psoriasis. Br. J. Dermatol. 2021, 185, 887–898. [CrossRef]
11] Nickoloff BJ, Nestle FO. Recent insights into the immunopathogeness of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113: 1664-75.
15]Taléns-Visconti R, Perra M, Ruiz-Saurí A, Nácher A. New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases. Pharmaceutics. 2022 Nov 22;14(12):2558. doi: 10.3390/pharmaceutics14122558. PMID: 36559053; PMCID: PMC9786812
16] Huang TH, Lin CF, Alalaiwe A, Yang SC, Fang JY. Apoptotic or Antiproliferative Activity of Natural Products against Keratinocytes for the Treatment of Psoriasis. Int J Mol Sci. 2019 May 24;20(10):2558. doi: 10.3390/ijms20102558. PMID: 31137673; PMCID: PMC6566887.
17]Hrehorów E, Salomon J, Matusiak L, Reich A, Szepietowski JC. Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2012 Jan;92(1):67-72. doi: 10.2340/00015555-1193. PMID: 21879243.
18] Joshi R. Immunopathogenesis of psoriasis. India J Dermatol Venereol Leprol 2004;70:1.
19]Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2:151‑61.
20]McGregor JM, Barker JN, Ross EL, MacDonald DM. Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: In situ expression of beta 2‑integrins. J Am Acad Dermatol 1992;27:383‑8.
21]Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti‑angiogenic therapy: Rationale, challenges and clinical studies. Angiogenesis 2002;5:237‑56.
22] Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis 2002;5:231‑6.
23]Salgado-Boquete, L.; Carrascosa, J.M.; Llamas-Velasco, M.; Ruiz-Villaverde, R.; de la Cueva, P.; Belinchón, I. A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis? Life 2021, 11, 627. [CrossRef]
24]Mrowietz, U.; Kragballe, K.; Reich, K.; Spuls, P.; Griffiths, C.E.; Nast, A.; Franke, J.; Antoniou, C.; Arenberger, P.; Balieva, F.; et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch. Dermatol. Res. 2011, 303, 1–10. [CrossRef]
25]Oranje, A.P.; Marcoux, D.; Svensson, A.; Prendiville, J.; Krafchik, B.; Toole, J.; Rosenthal, D.; de Waard-van der Spek, F.B.; Molin, L.; Axelsen, M. Topical calcipotriol in childhood psoriasis. J. Am. Acad. Dermatol. 1997, 36, 203–208. [CrossRef]
26]Maul, J.T.; Anzengruber, F.; Conrad, C.; Cozzio, A.; Häusermann, P.; Jalili, A.; Kolios, A.G.A.; Laffitte, E.; Lapointe, A.K.; Mainetti, C.; et al. Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology 2021, 237, 166–178.
27]Elmets, C.A.; Korman, N.J.; Prater, E.F.; Wong, E.B.; Rupani, R.N.; Kivelevitch, D.; Armstrong, A.W.; Connor, C.; Cordoro, K.M.; Davis, D.M.R.; et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J. Am. Acad. Dermatol. 2021, 84, 432–470. [CrossRef]
28]Armstrong, A.W.; Puig, L.; Joshi, A.; Skup, M.; Williams, D.; Li, J.; Betts, K.A.; Augustin, M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020, 156, 258–269. [CrossRef]
29]Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(1):S39-S49.